Tempest Therapeutics, Inc.

TPST Nasdaq SEC CIK 1544227
Follow Tempest Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.6M −3.4% vs same quarter last year
EPS, diluted −$0.21 +73.4% vs same quarter last year
Operating cash flow −$2.1M +69.7% vs same quarter last year
Operating income −$2.8M +21.5% vs same quarter last year
Net income by quarter
−$13.8M
−$10.9M
−$7.9M
−$3.5M
−$4M
−$27.7M
−$5.2M
−$3.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$100M−$75M−$50M−$25M$0$25MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$26.3M
FY24-−$41.8M
FY23-−$29.5M
FY22-−$35.7M
FY21-−$28.3M
FY20-−$19.2M
FY19-−$44.6M
FY18-−$27.2M
FY17$295K−$84.6M
FY16$653K−$82.3M
FY15$277K−$73.2M
FY14$0−$49.5M
FY13$0−$29M
FY12-−$13.5M
FY11--
MarginsShare of revenue
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20--
FY19--
FY18--
FY17−28585.1%−28670.5%
FY16−12406.1%−12597.2%
FY15−25992.4%−26432.9%
FY14--
FY13--
FY12--
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$26.8M
FY24−$33.5M
FY23−$27.5M
FY22−$31.6M
FY21−$26.1M
FY20−$19.1M
FY19−$41.6M
FY18−$23.7M
FY17−$20.3M
FY16−$64.3M
FY15−$55.5M
FY14−$33.4M
FY13−$18.8M
FY12−$12M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Tempest Therapeutics
  • Healthcare median
−30000%−20000%−10000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearTempest TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17−28670.5%−45.9%
FY16−12597.2%−36%
FY15−26432.9%−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%